Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra for colchicine-resistant familial Mediterranean fever in Chinese patients
ChiCTR2400091998Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Apr 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anakinra in Familial Mediterranean fever (FMF), sponsored by Beijing Children's Hospital. Primary endpoint: Change in monthly FMF attack frequency from baseline to Month 6. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
anakinra
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on ChiCTR2400091998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091998.